"sars-cov-2"

Air purifier maker Aurabeat launches USFDA-approved anti-Covid medical device for SARS-COV-2 disinfection in India

At least eight districts including Hyderabad, continue to report higher number of Covid infections daily

A south-central Yunnan origin is a highly suggestive finding because at the centre of that region is the Mojiang mine, which is the focus of most lab origin theories

Variant remains active in at least 10 districts, including areas under GHMC

The WHO listed "vaccine hesitancy" as among the top 10 threats to global health.

Overall, the INSACOG has reported 70 Delta Plus confirmed cases in the country out of which 23 were reported in Maharashtra, 10 in Tamil Nadu, 11 in Madhya Pradesh, four in Chandigarh, three each from Kerala and Karnataka.

Although SARS-CoV-2, the virus causing Covid-19, primarily affects the respiratory tract, it also leads to cardiovascular complications including severe arrhythmias, acute coronary syndromes, myocarditis and pulmonary embolism.

Daily new Covid infections fail to drop significantly unlike the first wave due to the variant

The rate of mortality was found to be about 50% lower in fully vaccinated individuals having a breakthrough infection, according to CCMB, AIg study

The study, which was conducted in collaboration with Stanford University, appeared in the Journal of the American Medical Association.

The team, which includes Australian Nobel laureate Professor Peter Doherty, also has scientists from the UK, the US, China, Canada, New Zealand. The study was released on open-access repository Zenodo

Hyderabad-based pharma company has approached the Drug Controller General of India to seek Emergency Use Authorization for the investigational drug in India

If there is a SARS-CoV-2 mutant that has the ability to escape immunity, then the size of the third wave could be significant, suggests the study

Efficacy data also demonstrates 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant, the company said in a statement while announcing its phase 3 data analysis.

Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus.

On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply the drug for the treatment of Covid-19 in India

China earlier this month, authorised the emergency use of CoronaVac, for children aged between 3 and 17 years.

Even 15 weeks after the first dose, eight of 10 people still had detectable germinal centers containing B cells targeting the virus.

Scientists are worried about the Delta plus variant due to the presence of Beta variant and the features of the Delta variant in it, which can make it more infectious

Now, researchers at Washington University School of Medicine in St. Louis have found that a single mutation gives SARS-CoV-2 the ability to enter cells through another route - one that does not require ACE2.